AUS
NZ
UK
CA
USA
IND
_10_04_2024_16_38_50_427275.jpg)
Highlights
- DRI Healthcare Trust invests $57 million in Editas Medicine's payment rights linked to Vertex's CASGEVY® gene-editing therapy.
- CASGEVY® is the first FDA-approved treatment using CRISPR technology for sickle cell disease and transfusion-dependent beta thalassemia.
- This strategic move enhances DRI's portfolio while supporting the development of innovative therapies.
In a significant development for the biotech and healthcare investment landscape, DRI Healthcare Trust (TSX: DHT.UN, DHT.U) has announced the acquisition of payment rights associated with Editas Medicine, Inc.'s Cas9 gene-editing technology for CASGEVY® (exagamglogene autotemcel). The wholly owned subsidiary of the Trust completed this transaction for an upfront purchase price of $57 million, indicating a robust commitment to advancing innovative medical therapies.
CASGEVY® holds the distinction of being the first treatment approved by the U.S. Food and Drug Administration (FDA) to utilize CRISPR technology, specifically aimed at addressing serious genetic disorders. Approved in December 2023 for sickle cell disease (SCD) and January 2024 for transfusion-dependent beta thalassemia (TDT), the therapy has also garnered approval from the European Medicines Agency for both conditions. Notably, it stands as the only gene-edited cell therapy available for patients suffering from these debilitating diseases.
Sickle cell disease is an inherited blood disorder characterized by severe pain, organ damage, and a reduced lifespan due to the presence of misshapen red blood cells. Meanwhile, transfusion-dependent beta thalassemia requires regular blood transfusions to manage anemia, which can lead to fatigue, shortness of breath, and various organ complications. Both conditions significantly diminish patients' quality of life and can lead to life-threatening complications.
The financial structure of the acquisition allows DRI Healthcare Trust to benefit from a variety of payments stemming from a sublicensing agreement between Editas and Vertex Pharmaceuticals. The Trust is entitled to a portion of the annual license fees, which range from $5 million to $40 million, as well as specific sales-based increases. Additionally, DRI will receive a mid-double-digit percentage of a potential $50 million contingent payment that Editas is eligible for under the agreement with Vertex. The first payment from this arrangement is anticipated in January 2025, with payment streams continuing until 2034.
Ali Hedayat, Acting Chief Executive Officer of the Trust's investment manager, expressed enthusiasm about diversifying the Trust's portfolio into a new therapeutic area. "The structure of this transaction demonstrates our ability to work with leading innovators to find flexible non-dilutive financing options," he noted, highlighting the potential for reinvestment into vital business priorities.
Navin Jacob, Chief Investment Officer of the investment manager, further emphasized the significance of the acquisition, stating, "This aligns with our commitment to supporting transformative therapies that can substantially improve patients' lives." He praised the collaborative efforts with Editas, which resulted in a timely closure of the transaction while ensuring mutual benefits.
As the global healthcare landscape continues to evolve, DRI Healthcare Trust's investment in CASGEVY® not only strengthens its financial position but also underscores its commitment to supporting groundbreaking therapies that address critical healthcare needs. This strategic acquisition may well pave the way for further innovations in gene-editing technologies, offering hope to patients affected by severe genetic disorders.
